Phase 3 Stroke Trial, Recruiting (NCT05293080)

Phase 3 Stroke Trial, Recruiting NCT05293080 Sponsor: Universitätsklinikum Hamburg-Eppendorf Condition: Stroke

Printed from Voxsanity (voxsanity.com.au) — NCT05293080 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Stroke

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have had an ischemic stroke (a stroke caused by a blood clot) in the past four weeks, confirmed by a brain scan (CT or MRI) or a doctor's assessment
It is possible for you to begin the trial treatment within four weeks of your stroke, when your doctors feel it is safe to do so
You were first found to have atrial fibrillation (an irregular heartbeat) no more than one year before joining the trial
You are able and willing to give your consent to take part in the trial

Who may not be able to join:

You have an advanced cancer or another serious illness where your life expectancy is expected to be less than 12 months
You have previously had a procedure or surgery specifically to treat your atrial fibrillation
Your heart condition means that a certain type of treatment aimed at restoring a normal heart rhythm is not considered suitable for you (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Götz Thomalla, MD, Universitätsklinikum Hamburg-Eppendorf

Phone: +4940741053770

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05293080

Sponsor: Universitätsklinikum Hamburg-Eppendorf

Phase: Phase 3

Status: Recruiting

Condition: Stroke

Trial contact: +4940741053770

More information: https://clinicaltrials.gov/study/NCT05293080

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have had an ischemic stroke (a stroke caused by a blood clot) in the past four weeks, confirmed by a brain scan (CT or MRI) or a doctor's assessment
It is possible for you to begin the trial treatment within four weeks of your stroke, when your doctors feel it is safe to do so
You were first found to have atrial fibrillation (an irregular heartbeat) no more than one year before joining the trial
You are able and willing to give your consent to take part in the trial

Who may not be able to join:

You have an advanced cancer or another serious illness where your life expectancy is expected to be less than 12 months
You have previously had a procedure or surgery specifically to treat your atrial fibrillation
Your heart condition means that a certain type of treatment aimed at restoring a normal heart rhythm is not considered suitable for you (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Registry

ClinicalTrials.gov

Start date

6 November 2025

Est. completion

1 July 2031

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Time to first recurrent stroke, cardiovascular death, or hospitalization due to worsening of heart failure or due to acute coronary syndrome.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov